戻る Agenda
What Do We Do Now? Why You Need A Resource for Ethical Questions During Drug Development
Session Chair(s)
Karla Childers, MS
Vice President, Bioethics, Policy & Partnerships
Johnson & Johnson, United States
Complex ethical questions are inherent in drug development. Teams need resources to provide independent, thoughtful and informed assistance with these questions. We will look at models of ethical consultation that match organizational needs.
Learning Objective : Recognize situations in which ethical consultation may be appropriate, useful and necessary; Identify potential resources to provide ethical consultation appropriate to the needs of the development program; Describe how to obtain ethical consultation in advance of situations in which it may be necessary.
Speaker(s)
Models for Bioethical Consultation to Drug Development Teams
Lindsay McNair, MD, MPH, MS
Equipoise Consulting, United States
Principal Consultant